Combination Chemotherapy with Paclitaxel, Estramustine and Carboplatin for Hormone Refractory Prostate Cancer
- 1 December 2002
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 168 (6) , 2444-2450
- https://doi.org/10.1016/s0022-5347(05)64164-x
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopeniaCancer Chemotherapy and Pharmacology, 2001
- Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780Journal of Clinical Oncology, 2001
- Paclitaxel, Estramustine Phosphate, and Carboplatin in Patients With Advanced Prostate CancerJournal of Clinical Oncology, 2001
- Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitroCancer, 1999
- Vinblastine Versus Vinblastine Plus Oral Estramustine Phosphate for Patients With Hormone-Refractory Prostate Cancer: A Hoosier Oncology Group and Fox Chase Network Phase III TrialJournal of Clinical Oncology, 1999
- Effect of carboplatin on response and palliation in hormone-refractory prostate cancerSupportive Care in Cancer, 1998
- Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.Journal of Clinical Oncology, 1997
- Cytotoxic chemotherapy for advanced hormone-resistant prostate cancerCancer, 1993
- Carboplatin in advanced hormone refractory prostatic cancer patientsEuropean Journal Of Cancer, 1993
- Reporting results of cancer treatmentCancer, 1981